Axsome Therapeutics vs Chemed
Axsome Therapeutics (AXSM), health care, and Chemed (CHE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Axsome Therapeutics and Chemed are valued at about the same: $7.2B and $7.1B. Axsome Therapeutics's operating margin in its latest fiscal year was -26.1% and Chemed's 13.4%. Over the past year Axsome Therapeutics's share price has moved -7.10% and Chemed's +26.2%.
Key facts
- Axsome Therapeutics market value
- $7.2B
- Chemed market value
- $7.1B
- Chemed P/E
- 26.2
- Axsome Therapeutics revenue
- $638.5MFY to 2025-12-31
- Chemed revenue
- $2.5BFY to 2025-12-31
Market values as of .
| Measure | Axsome Therapeutics | Chemed |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.2Bhigher | $7.1Blower |
| Revenue | $638.5Mlower | $2.5Bhigher |
| Earnings | -$183.2Mlower | $265.2Mhigher |
| Employees | 1,390lower | 15,811higher |
| Total assets | $689.8Mlower | $1.5Bhigher |
| Valuation | ||
| P/E | — | 26.2 |
| P/S | 11.2higher | 2.8lower |
| P/B | 67.8higher | 8.2lower |
| Dividend yield | 0.00%lower | 0.46%higher |
| Profitability | ||
| Operating margin | -26.1%lower | 13.4%higher |
| Balance sheet | ||
| Net assets | $88.3Mlower | $979.4Mhigher |
| Total liabilities | $601.5Mhigher | $558.8Mlower |
| Total debt | $187.7M | — |
| Cash on hand | $322.9Mhigher | $74.5Mlower |
| Price change | ||
| Today | -0.77%lower | -0.49%higher |
| 1 year | -7.10%lower | +26.2%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Axsome Therapeutics only (0)
None of the tracked investors.
Chemed only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns AXSM · Who owns CHE
More on Axsome Therapeutics
Further comparisons
Axsome Therapeutics against its closest peers
Chemed against its closest peers
Learn
Questions and answers
Which is bigger, Axsome Therapeutics or Chemed?
By market value, Axsome Therapeutics is the larger: $7.2B against $7.1B for Chemed. By revenue in its latest fiscal year, Chemed is the larger: $2.5B against $638.5M for Axsome Therapeutics.
Which has the higher operating margin?
Chemed: 13.4%, against -26.1% for Axsome Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Chemed: 0.46%, against 0.00% for Axsome Therapeutics. Dividend yield is the last twelve months' dividends as a share of today's share price.
Cite this page
Funkfolio, “Axsome Therapeutics vs Chemed”, data as of 18 November 2026. https://funkfolio.com/compare/axsm-vs-che
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.